Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance

Haematologica

Volumn 102, Issue 10, 2017, Pages 1650-1660

  Stivala, Simona ^a,b   Gobbato, Sara ^a,b   Infanti, Laura ^c   Reiner, Martin F ^a,b   Bonetti, Nicole ^a,b   Meyer, Sara C ^d   Camici, Giovanni G ^a   Lüscher, Thomas F ^e   Buser, Andreas ^c   Beer, Jürg H ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Kantonsspital Baden   (Switzerland)

^c Regional Blood Transfusion Service of the Swiss Red Cross   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; CASPASE 3; COLLAGEN; CYCLOHEXIMIDE; FLUORESCEIN ISOTHIOCYANATE; GLYCOCALICIN; GLYCOPROTEIN IB; LECTIN; MITOGEN ACTIVATED PROTEIN KINASE P38; N ACETYLGLUCOSAMINE; PROTEIN BAK; SIALIDASE; SIALIDASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ADHESION RECEPTOR; FUROCOUMARIN DERIVATIVE; PROTEIN BINDING; THROMBIN RECEPTOR; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APHERESIS; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CLEARANCE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; NORMAL HUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCID MOUSE; THROMBOCYTE AGGREGATION; THROMBOCYTE LIFESPAN; TRANSFUSION MEDICINE; ULTRAVIOLET A RADIATION; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; DRUG EFFECT; METABOLISM; PROTEIN SYNTHESIS; RADIATION RESPONSE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; ULTRAVIOLET RADIATION;

ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BLOOD PLATELETS; CELL SURVIVAL; COLLAGEN; FUROCOUMARINS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; ULTRAVIOLET RAYS; VON WILLEBRAND FACTOR;

EID: 85030312765     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2017.164137     Document Type: Article

References (54)

1. Hersh EM, Bodey GP, Nies BA, Freireich EJ. Causes of death in acute leukemia: a ten-year study of 414 patients from 1954-1963. JAMA. 1965;193:105-109.
2. Mayr WR. Blood transfusion in Europe-The White Book 2005: The patchwork of transfusion medicine in Europe. Transfus Clin Biol. 2005;12:357-358.
3. Whitaker B, Rajbhandary S, Kleinman S, Harris A, Kamani N. Trends in United States blood collection and transfusion: results from the 2013 AABB Blood Collection, Utilization, and Patient Blood Management Survey. Transfusion. 2016; 56(9):2173-2183.
4. Heal JM, Singal S, Sardisco E, Mayer T. Bacterial proliferation in platelet concentrates. Transfusion. 1986;26(4):388-390.
5. Butler C, Doree C, Estcourt LJ, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane database Syst Rev. 2013;3(3):CD009072.
6. Solheim BG. Pathogen reduction of blood components. Transfus Apher. Sci. 2008;39(1473):75–82.
7. Picker SM. Current methods for the reduction of blood-borne pathogens: A comprehensive literature review. Blood Transfus. 2013;11:343-348.
8. Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood SystemTM. Transfus Med Hemother. 2011; 38(1):19-31.
9. Lozano M, Knutson F, Tardivel R, et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol. 2011;153(3):393–401.
10. Kerkhoffs JLH, Van Putten WLJ, Novotny VMJ, et al. Clinical effectiveness of leucore-duced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol. 2010;150(2):209–217.
11. van Rhenen D, Gulliksson H, Cazenave J-P, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood. 2003; 101(6):2426-2433.
12. TM: a cohort study. Transfus Apher Sci. 2011; 45(2):175-181.
13. Vamvakas EC. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang. 2012;102(4):302-316.
14. Sigle J-P, Infanti L, Studt J-D, et al. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components. Transfusion. 2013; 53(8):1788-1797.
15. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial Blood. 2004; 104(5):1534-1541.
16. Picker SM, Oustianskaia L, Schneider V, Gathof BS. Annexin V release and transmembrane mitochondrial potential during storage of apheresis-derived platelets treated for pathogen reduction. Transfus Med Hemother. 2010;37(1):7-12.
17. Reid S, Johnson L, Woodland N, Marks DC. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling. Transfusion. 2012;52(10):2094-2103.
18. Prudent M, D’Alessandro A, Cazenave JP, et al. Proteome changes in platelets after pathogen inactivation-an interlaboratory consensus. Transfus Med Rev. 2014; 28(2):72-83.
19. Abonnenc M, Sonego G, Kaiser-Guignard J, et al. In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step. Blood Transfus. 2015;13(2):255-264.
20. Picker SM, Oustianskaia L, Schneider V, Gathof BS. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang. 2009;97(1):26-33.
21. Schubert P, Coupland D, Culibrk B, Goodrich RP, Devine D V. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion. 2013;53(12):3164-3173.
22. Chen Z, Schubert P, Culibrk B, Devine D V. p38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treat- ment. Transfusion. 2014;1-10.
23. Stivala S, Reiner MF, Lohmann C, et al. Dietary -linolenic acid increases the platelet count in ApoE-/- mice by reducing clearance. Blood. 2013;122(6):1026-1033.
24. Boylan B, Berndt MC, Kahn ML, Newman PJ. Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti-human platelet agents. Blood. 2006;108(3):908-914.
25. Dowling MR, Josefsson EC, Henley KJ, Hodgkin PD, Kile BT. Platelet senescence is regulated by an internal timer, not damage inflicted by hits. Blood. 2010; 116(10):1776-1778.
26. Sørensen AL, Rumjantseva V, Nayeb-Hashemi S, et al. Role of sialic acid for platelet life span: exposure of beta-galac-tose results in the rapid clearance of platelets from the circulation by asialogly-coprotein receptor-expressing liver macrophages and hepatocytes. Blood. 2009;114(8):1645-1654.
27. Kile BT. The role of the intrinsic apoptosis pathway in platelet life and death. J. Thromb. Haemost. 2009;7 Suppl 1:214-217.
28. Bergmeier W, Burger PC, Piffath CL, et al. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood. 2003;102(12):4229-4235.
29. Weyrich a S, Dixon D a, Pabla R, et al. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci USA. 1998;95(10):5556-5561.
30. Grozovsky R, Hoffmeister KM, Falet H. Novel clearance mechanisms of platelets. Curr Opin Hematol. 2010;17(6):585-589.
31. Li J, van der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun. 2015;6:7737.
32. Hechler B, Ohlmann P, Chafey P, et al. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion. 2013; 53(6):1187-1200.
33. Moog S, Mangin P, Lenain N, et al. Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation. Blood. 2001;98(4):1038-1046.
34. Canault M, Duerschmied D, Brill A, et al. p38 mitogen-activated protein kinase activation during platelet storage: consequences for platelet recovery and hemostatic function in vivo. Blood. 2010; 115(9):1835-1842.
35. Jansen a JG, Josefsson EC, Rumjantseva V, et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIb metalloproteinase-mediated cleavage in mice. Blood. 2012;119(5):1263-1273.
36. Moshfegh K, Lengweiler S, Häner M, et al. Fine structural and functional consequences of deglycosylation of the platelet adhesion receptor GPIb-IX (CD 42b). Biochem. Biophys Res Commun. 1998;249(3):903-909.
37. Leytin V, Allen DJ, Gwozdz A, Garvey B, Freedman J. Role of platelet surface glycoprotein Ibalpha and P-selectin in the clearance of transfused platelet concentrates. Transfusion. 2004;44(10):1487-1495.
38. Hoffmeister KM, Josefsson EC, Isaac N a, et al. Glycosylation restores survival of chilled blood platelets. Science. 2003; 301(5639):1531-1534.
39. Rumjantseva V, Grewal PK, Wandall HH, et al. Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med. 2009;15(11):1273-1280.
40. Brill A, Chauhan AK, Canault M, et al. Oxidative stress activates ADAM17/TACE and induces its target receptor shedding in platelets in a p38-dependent fashion. Cardiovasc Res. 2009;84(1):137-144.
41. Sandgren P, Diedrich B. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: Preservation of in vitro function. Vox Sang. 2015; 108(4):340-349.
42. Ali SF. Platelet activation of platelet concentrates derived from buffy coat and apheresis methods. Transfus Apher Sci. 2011;44(1):11-13.
43. Böck M, Rahrig S, Kunz D, Lutze G, Heim MU. Platelet concentrates derived from buffy coat and apheresis: Biochemical and functional differences. Transfus Med. 2002; 12(5):317-324.
44. Skripchenko A, Thompson-Montgomery D, Awatefe H, Turgeon a., Wagner SJ. Addition of sialidase or p38 MAPK inhibitors does not ameliorate decrements in platelet in vitro storage properties caused by 4 °C storage. Vox Sang. 2014;360-367.
45. Chen W, Liang X, Syed AK, et al. Inhibiting GPIbα shedding preserves post-transfusion recovery and hemostatic function of platelets after prolonged storage. Arterioscler Thromb Vasc Biol. 2016; ATVBAHA.116.307639.
46. Rukoyatkina N, Mindukshev I, Walter U, Gambaryan S. Dual role of the p38 MAPK/cPLA2 pathway in the regulation of platelet apoptosis induced by ABT-737 and strong platelet agonists. Cell Death Dis. 2013;4(11):e931.
47. Lindemann S, Tolley ND, Dixon D a, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol. 2001;154(3):485-490.
48. Osman A, Hitzler WE, Meyer CU, et al. Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets. 2014;1-14.
49. Van Aelst B, Feys HB, Devloo R, et al. Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro. Vox Sang. 2015;108(4):328-339.
50. Prudent M, Crettaz D, Delobel J, Tissot J-D, Lion N. Proteomic analysis of Intercept-treated platelets. J Proteomics. 2012;76 Spec No(Srts Vd):316-328.
51. Julmy F, Ammann RA, Fontana S, et al. Transfusion efficacy of apheresis platelet concentrates irradiated at the day of transfusion is significantly superior compared to platelets irradiated in advance. Transfus Med Hemotherapy. 2014;41(3):176-181.
52. Hess JR, Pagano MB, Barbeau JD, Johannson PI. Will pathogen reduction of blood components harm more people than it helps in developed countries¿ Transfusion. 2016;56(5):1236-1241.
53. Devine DV, Schubert P. Pathogen Inactivation Technologies. Hematol Oncol Clin North Am. 2016;30(3):609-617.
54. Corash L, Benjamin RJ. The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultraviolet A pathogen reduction treatment model. Transfusion. 2016; 56(March):S29-S38.